We are live on ! Find out more
NERM

New England Research & Management Portfolio holdings

AUM $257M
1-Year Est. Return 25.66%
This Fund
S&P 500
This Quarter Est. Return
-2.57%
1 Year Est. Return
+25.66%
3 Year Est. Return
+56.38%
5 Year Est. Return
+58.71%
10 Year Est. Return
+176.32%
AUM
$193M
AUM Growth
-$14M
Cap. Flow
-$5.91M
Cap. Flow %
-3.07%
Top 10 Hldgs %
24.03%
Holding
208
New
31
Increased
43
Reduced
64
Closed
52

Top Sells

Rank Stock Value
1
PLD
PROLOGIS
PLD
+$2.01M
2
ADI icon
Analog Devices
ADI
+$1.86M
3
HLT
HILTON HOTELS CORP
HLT
+$1.83M
4
V icon
Visa
V
+$1.78M
5
CCI icon
Crown Castle
CCI
+$1.63M

Sector Composition

Rank Sector Weight
1 Industrials 21.29%
2 Healthcare 15.89%
3 Financials 14.27%
4 Technology 13.65%
5 Consumer Staples 12.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GS icon
76
Goldman Sachs
GS
$284B
$864K 0.45%
2,618
+718
+38% +$254K
BX icon
77
Blackstone
BX
$95.1B
$863K 0.45%
+6,800
New +$829K
MET icon
78
MetLife
MET
$62.4B
$805K 0.42%
+11,450
New +$774K
QCOM icon
79
Qualcomm
QCOM
$201B
$773K 0.4%
5,055
+3,680
+268% +$617K
TER icon
80
Teradyne
TER
$52B
$769K 0.4%
6,504
-5,480
-46% -$694K
AZN icon
81
AstraZeneca
AZN
$251B
$766K 0.4%
5,775
-2,138
-27% -$256K
FANG icon
82
Diamondback Energy
FANG
$59.2B
$727K 0.38%
+5,300
New +$689K
MAR icon
83
Marriott International
MAR
$87.9B
$726K 0.38%
+4,132
New +$687K
BMRN icon
84
BioMarin Pharmaceuticals
BMRN
$12.5B
$722K 0.37%
9,363
+4,351
+87% +$364K
ELAN icon
85
Elanco Animal Health
ELAN
$11.5B
$708K 0.37%
27,150
+2,600
+11% +$69.2K
CL icon
86
Colgate-Palmolive
CL
$69.4B
$678K 0.35%
8,938
AMD icon
87
Advanced Micro Devices
AMD
$823B
$666K 0.35%
6,091
+161
+3% +$19.2K
REGN icon
88
Regeneron Pharmaceuticals
REGN
$79.7B
$661K 0.34%
946
-29
-3% -$18.3K
HPE icon
89
Hewlett Packard
HPE
$74.2B
$660K 0.34%
+39,525
New +$663K
AMGN icon
90
Amgen
AMGN
$203B
$643K 0.33%
2,660
-100
-4% -$23K
NDAQ icon
91
Nasdaq
NDAQ
$49.9B
$637K 0.33%
+10,725
New +$635K
FDX icon
92
FedEx
FDX
$73B
$627K 0.33%
2,711
-50
-2% -$11.7K
IR icon
93
Ingersoll Rand
IR
$27.9B
$622K 0.32%
+12,350
New +$662K
INTC icon
94
Intel
INTC
$513B
$611K 0.32%
12,333
+3,500
+40% +$173K
FCX icon
95
Freeport-McMoran
FCX
$99.6B
$586K 0.3%
+11,788
New +$522K
TROW icon
96
T. Rowe Price
TROW
$22.2B
$565K 0.29%
+3,735
New +$577K
AXTA icon
97
Axalta
AXTA
$7.12B
$562K 0.29%
22,875
-650
-3% -$18.2K
LRCX icon
98
Lam Research
LRCX
$339B
$562K 0.29%
10,450
-500
-5% -$29.1K
BEN icon
99
Franklin Templeton
BEN
$16.9B
$547K 0.28%
+19,590
New +$598K
AMCR icon
100
Amcor
AMCR
$19.6B
$533K 0.28%
9,403
+2,251
+31% +$131K

Similar funds

New England Research & Management's Q1 2022 Portfolio in Review

As of Q1 2022, New England Research & Management held 208 positions worth $193M, down 6.8% from $207M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

New England Research & Management withdrew a net $5.91M in Q1 2022, closing 52 positions and reducing 64 holdings. Its most notable exit was PROLOGIS, an estimated $2.01M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.

Against the trend, New England Research & Management opened a new position in C.H. Robinson worth $2.05M.

  • New England Research & Management's largest Q1 2022 buy was C.H. Robinson: 19,025 shares worth $2.05M.
  • New England Research & Management added most to Prosperity Bancshares in Q1 2022, an estimated $1.77M increase.
  • New England Research & Management's biggest Q1 2022 reduction was Analog Devices, cutting an estimated $1.86M.
  • New England Research & Management fully exited PROLOGIS in Q1 2022, selling an estimated $2.01M.
  • New England Research & Management's ten largest holdings make up 24% of its $193M portfolio in Q1 2022.
  • New England Research & Management opened 31 new positions and closed 52 in Q1 2022.
  • New England Research & Management's portfolio value fell 6.8% quarter-over-quarter to $193M.

Based on New England Research & Management's 13F filing for Q1 2022, filed 20 Apr 2022.